◼ Archived
Business
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug.
Pharma
12 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Novartis to License Drug From China’s Abogen in Up to $7.8 Billion Deal
Novartis strikes a massive licensing agreement worth up to $7.8 billion with China-based biotech firm Abogen.
◼ Archived
Business
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
◼ Archived
Business
Pharma's new top lobbyist is a former House majority leader
Eric Cantor, the former House majority leader, has been selected as the new president and chief executive officer of PhRMA.
◼ Archived
Business
GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
GLP-1 drug manufacturers face a surge of lawsuits as patients report permanent vision loss and blindness without prior warnings.
◼ Archived
Business
Enveda Raises $311 Million From Leading AI and Biotech Investors to Bring Pharma Into the 21st Century
Enveda secures $311 million in venture funding to advance nature-derived AI drugs into clinical trials.
◼ Archived
Business
Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✗
Novartis’s Latest Trial Setback Sinks Stock
Novartis shares drop significantly following multiple trial setbacks and difficult dealmaking in the pharmaceutical sector.
◼ Archived
Business
🔮 fades ✓
A New Use for GLP-1s? Amylyx Pharma Catapults To 3-Year High
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Pharma Company And Drug Testing Industry Claim Trump's Rescheduling Move Will 'Increase Marijuana Abuse'
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Vertex Pharma Makes A $10 Billion Deal; Crinetics Stock Doubles
Vertex Pharma's $10 billion purchase of Crinetics sparks a near‑doubling of its shares and a biotech‑M&A surge
◼ Archived
Business
🔮 fades
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.